HDV coinfection tracks with worse liver injury in Mauritanian chronic hepatitis B
Chronic hepatitis B remains highly endemic in Mauritania, and the new molecular survey from Nouakchott shows why hepatitis delta virus deserves far more clinical attention in this setting. Among 165 adults with chronic hepatitis B at the National Institute of Hepato-Viology, HDV coinfection was common enough to alter the clinical picture in a meaningful way: patients with detectable HDV RNA carried more symptoms, higher AST, ALT, and AFP values, and higher APRI and FIB-4 scores than those without active HDV replication. The pattern fits the biology of delta infection. HDV depends on HBV for entry and assembly, but once established it can drive disproportionately aggressive liver injury, often out of proportion to the HBV DNA level itself.
The virologic burden in this cohort was mixed but clinically revealing. HBV DNA was detectable in 146 of 165 patients, with a median level of 2,197.25 IU/mL, and 75 patients exceeded the 2,000 IU/mL threshold. Total anti-HDV antibodies were found in 68 of 112 tested patients, and HDV RNA was detected in 34 of 130 patients, with a median level of 72,271 IU/mL. Among anti-HDV-positive participants, half had detectable HDV RNA. This matters at the bedside because seropositivity alone does not distinguish prior exposure from active replication. In a disease where treatment choices and prognosis hinge on ongoing viral activity, RNA testing provides the clinical clarity that antibody testing cannot.
HDV positivity lined up with more advanced disease. Patients with detectable HDV RNA had higher rates of cirrhosis and hepatocellular carcinoma, and they were more likely to be receiving treatment. The association with lower HBV DNA detectability is a classic feature of delta coinfection: HDV can suppress HBV replication while still accelerating hepatic inflammation and fibrogenesis. In practical terms, a lower HBV DNA does not reassure when HDV is active. The liver can be under greater immunologic and fibrotic stress even when the HBV signal appears muted.
HBV genotype D dominates, with recombinant lineages and limited resistance signals
The molecular map of HBV in this cohort was more diverse than a simple genotype count suggests. Of the 65 sequences analyzed, genotype D was most common, accounting for 36 isolates, followed by genotype E in 21 and genotype A in 8. Within genotype D, 11 isolates were assigned to subgenotype D8, a D/E recombinant lineage first described in Niger. Whole-genome analysis also identified co-circulating HBV genotypes A, D, and E, including A1, A2, D1, D4, E, and recombinant D/E strains. The presence of recombination is not an academic footnote. Viral recombination can reshape transmission networks and complicate phylogenetic inference, and it signals sustained viral circulation across overlapping local and regional lineages.
The HBV genome analysis also found an rtA181S substitution in the polymerase reverse-transcriptase domain and a naturally occurring altered YMDD motif, rtY203N. Even so, the overall genomic picture showed high conservation across coding regions and no widespread antiviral resistance in the samples studied. For clinicians, that combination is important. It suggests that the current burden of liver disease in Mauritania is being driven more by endemic transmission, delayed diagnosis, and HDV coinfection than by a large, already-established resistance problem. The practical implication is prevention and detection, not reflexive concern over treatment failure from resistance alone.
HDV genotyping added another layer. Among 21 typed isolates, HDV genotype 1 predominated, with two genotype 5 isolates also identified. Genotype 1 has a wide global distribution and is often associated with severe disease in many endemic regions, while genotype 5 is more geographically restricted. The mix seen here reinforces the need for local molecular surveillance rather than reliance on assumptions drawn from neighboring countries or from older epidemiologic patterns.
The laboratory phenotype matched the clinical picture. HDV RNA positivity was associated with higher AST, ALT, AFP, APRI, and FIB-4, all markers that point toward more active injury and more advanced fibrosis. AFP elevation, in particular, raises concern because it can accompany regenerative activity, fibrosis, or hepatocellular carcinoma risk in chronic liver disease. When those indices rise together, the signal is difficult to ignore. The liver is not simply inflamed; it is being pushed toward structural damage.
Screening and vaccination gaps stand out more sharply than the viral genetics
The most actionable message from the Mauritanian cohort is not the novelty of the genotypes, although the D8 recombinant lineage and the co-circulation of multiple HBV clades are epidemiologically important. The urgent issue is missed HDV detection in chronic hepatitis B care. Routine HDV screening is warranted in HBsAg-positive patients, especially when symptoms persist, transaminases rise, or fibrosis estimates worsen despite apparently modest HBV DNA levels. In a setting where HDV coinfection is frequent and linked to more severe liver injury, waiting for overt decompensation wastes the narrow window when surveillance and treatment can still alter the trajectory.
The study also points directly to prevention policy. Improved HBV vaccination coverage, including the birth dose, is central to reducing future HBV and HDV burden. Without early immunization, the pool of susceptible infants and children remains large enough to sustain ongoing transmission. Since HDV requires HBV as a helper virus, every prevented HBV infection blocks a potential HDV infection as well. That linkage gives hepatitis B vaccination an amplified public health value in Mauritania.
In the end, the molecular profile and the clinical phenotype tell the same story from different angles: HDV coinfection is frequent, often active, and associated with more advanced liver disease in Mauritanian patients living with chronic hepatitis B. The study is limited to adults enrolled in a single center in Nouakchott, and genotype data were available for only a subset of the cohort, but the signal remains strong enough to change clinical priorities. For hepatology services in Mauritania, the next step is not to wait for more elegant virology. It is to screen more consistently, vaccinate earlier, and identify HDV before fibrosis and carcinoma become the dominant diagnosis.